3-Methoxy-chinolin-carbonsaeure-(2) | 103856-60-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-Methoxy-chinolin-carbonsaeure-(2)
• 英文别名: 3-methoxy-quinoline-2-carboxylic acid；3-Methoxy-2-quinolinecarboxylic acid；3-methoxyquinoline-2-carboxylic acid
• CAS: 103856-60-6
• 化学式: C₁₁H₉NO₃
• 分子量: 203.197
• InChiKey: JJNRPVDJAVHGHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-Methoxy-chinolin-carbonsaeure-(2) 、 在 碳酸氢钠 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以84%的产率得到(N-(3-methoxyquinolinyl-2-carbonyl)-D-Ser-Pip-Gly-Sar-NMe-Val)2 (serine hydroxyl) dilactone
  参考文献：
  名称：

  Synthesis of key sandramycin analogs: systematic examination of the intercalation chromophore

  摘要：

  The preparation and examination of 2-22 constituting a systematic study of the chromophore of sandramycin (1) are detailed. Fluorescence quenching studies were used to establish binding constants for 1-24 within calf thymus DNA, within a single high affinity bis-intercalation binding site 5'-d(GCATGC)(2), and to establish the preference for sandramycin binding to 5'-d(GCXXGC)(2) where XX = AT, TA, GC, and CG. From the latter studies, sandramycin was found to exhibit a preference that follows the order: 5'-d(GCATGC)(2) > 5'-d(GCGCGC)(2), Delta Delta G degrees = 0.3 kcal/mol > 5'-d(GCTAGC)(2), 5'-d(GCCGGC)(2), Delta Delta G degrees = 0.6 kcal/mol although it binds with high affinity to all four deoxyoligonucleotides. The two highest affinity sequences constitute repeating 5'-PuPy motifs with each intercalation event occurring at a 5'-PyPu step. The most effective sequence constitutes the less stable duplex, contains the sterically most accessible minor groove central to the bis-intercalation site, and the ability to accept two gly-NH/T C2 carbonyl H-bonds identified in prior NMR studies. Similarly, the contribution of the individual structural features of the chromophore were assessed with the high affinity duplex sequence 5'-d(GCATGC)(2). To a first approximation, the cytotoxic properties were found to parallel trends established in the DNA binding affinities. The exception to this generalization was 4 which lacks the sandramycin chromophore phenol. Although typically 4-10x less potent than sandramycin against leukemia cell lines, it proved to be 1-10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting IC50 values of IpM-10 nM placing it among the most potent agents identified to date. Additionally, the first disclosure of the HIV-1 reverse transcriptase inhibitory activity of sandramycin (1) as well as that of its key analogs are described and define the chromophore structural features required for their exceptional potency. Two analogs, 18 and 3, roughly maintain the HIV-I reverse transcriptase inhibitory potency of 1 but exhibit substantially diminished cytotoxic activity (10(2) - 10(3)x). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(97)10014-1
• 作为产物：
  描述：

  methyl 3-hydroxyquinoline-2-carboxylate 在 lithium hydroxide 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-Methoxy-chinolin-carbonsaeure-(2)
  参考文献：
  名称：

  Synthesis of key sandramycin analogs: systematic examination of the intercalation chromophore

  摘要：

  The preparation and examination of 2-22 constituting a systematic study of the chromophore of sandramycin (1) are detailed. Fluorescence quenching studies were used to establish binding constants for 1-24 within calf thymus DNA, within a single high affinity bis-intercalation binding site 5'-d(GCATGC)(2), and to establish the preference for sandramycin binding to 5'-d(GCXXGC)(2) where XX = AT, TA, GC, and CG. From the latter studies, sandramycin was found to exhibit a preference that follows the order: 5'-d(GCATGC)(2) > 5'-d(GCGCGC)(2), Delta Delta G degrees = 0.3 kcal/mol > 5'-d(GCTAGC)(2), 5'-d(GCCGGC)(2), Delta Delta G degrees = 0.6 kcal/mol although it binds with high affinity to all four deoxyoligonucleotides. The two highest affinity sequences constitute repeating 5'-PuPy motifs with each intercalation event occurring at a 5'-PyPu step. The most effective sequence constitutes the less stable duplex, contains the sterically most accessible minor groove central to the bis-intercalation site, and the ability to accept two gly-NH/T C2 carbonyl H-bonds identified in prior NMR studies. Similarly, the contribution of the individual structural features of the chromophore were assessed with the high affinity duplex sequence 5'-d(GCATGC)(2). To a first approximation, the cytotoxic properties were found to parallel trends established in the DNA binding affinities. The exception to this generalization was 4 which lacks the sandramycin chromophore phenol. Although typically 4-10x less potent than sandramycin against leukemia cell lines, it proved to be 1-10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting IC50 values of IpM-10 nM placing it among the most potent agents identified to date. Additionally, the first disclosure of the HIV-1 reverse transcriptase inhibitory activity of sandramycin (1) as well as that of its key analogs are described and define the chromophore structural features required for their exceptional potency. Two analogs, 18 and 3, roughly maintain the HIV-I reverse transcriptase inhibitory potency of 1 but exhibit substantially diminished cytotoxic activity (10(2) - 10(3)x). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(97)10014-1

文献信息

• Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same
  申请人：Darwish Ihab S.

  公开号：US20090163511A1

  公开（公告）日：2009-06-25

  Disclosed are carboxamide, sulfonamide and amine compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure in which R 1 , R 2 , R 4 , D, E, J, T, p, q and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.

  揭示了羧酰胺、磺胺和胺类化合物，以及药物组合物和使用方法。其中一种实施例是具有以下结构的化合物 其中R 1 ，R 2 ，R 4 ，D，E，J，T，p，q和x如本文所述。在某些实施例中，本文所披露的化合物可以激活AMPK途径，并可用于治疗与代谢有关的疾病和症状。
• Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0650960A1

  公开（公告）日：1995-05-03

  Die Erfindung betrifft Verbindungen der Formel I, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel. Insbesondere werden die Verbindungen als Ester-Prodrugs von Prolylhydroxylase-Inhibitoren eingesetzt zur Hemmung der Kollagenbiosynthese, und als Fibrosuppressiva.

  本发明涉及式 I 的化合物、 的制备工艺及其作为药物的用途。特别是，这些化合物可用作脯氨酰羟化酶抑制剂的酯原药，以抑制胶原蛋白的生物合成，还可用作纤维抑制剂。
• Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0650961A1

  公开（公告）日：1995-05-03

  Die Erfindung betrifft Verbindungen der Formel I, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel. Insbesondere werden die Verbindungen eingesetzt zur Hemmung der Kollagenbiosynthese, als Inhibitoren der Prolylhydroxylase und als Fibrosuppressiva.

  本发明涉及式 I 的化合物、 的制备工艺及其作为药物的用途。特别是，这些化合物可用于抑制胶原蛋白的生物合成，作为脯氨酰羟化酶的抑制剂和纤维抑制剂。
• Substituierte Chinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Prolyl-4-hydroylase Inhibitoren
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0765871A1

  公开（公告）日：1997-04-02

  Die Erfindung betrifft substituierte Chinolin-2-carbonsäureamide der Formel I ihre Herstellung und ihre Verwendung sowie Zwischenproukte, die bei der Herstellung der Verbindungen der Formel I entstehen. Die erfindungsgemäßen Verbindungen werden als Inhibitoren der Prolyl-4-hydroxylase und als Arzneimittel zur Behandlung von fibrotischen Erkrankungen verwendet.

  本发明涉及式 I 的取代喹啉-2-羧酰胺类化合物 的制备及其用途，以及在制备式 I 化合物过程中形成的中间产物。 根据本发明的化合物可用作脯氨酰-4-羟化酶的抑制剂和治疗纤维化疾病的药物。
• SANDRAMYCIN ANALOGS
  申请人：The Scripps Research Institute

  公开号：EP0996458A1

  公开（公告）日：2000-05-03